Long lead times and high barriers to entry will restrict competition in the vaccines market, leaving GSK, Sanofi, Merck & Co. and Pfizer dominant, a Jefferies analyst says.
Bluebird Bio has reported encouraging efficacy and safety data from a Phase I trial of its CAR-T multiple myeloma therapy, bb2121.
Valitacell has moved into the National Institute for Bioprocessing Research and Training (NIBRT) as it works to further develop its cell performance technologies.
Arrowhead Pharmaceuticals Inc. has also laid off its Chief scientific officer David Lewis - as part of the 34 staff cull - after several trials using delivery vehicle Ex1 were stopped by the firm.
Takeda has started work on a vaccine plant to make its candidate Dengue fever virus vaccine, TAK-003.
The deaths in a trial of Juno Therapeutics’ JCAR015 are most likely product-specific says the CEO of French CAR-T developer TxCell, who rejected the idea that chemotherapy or the CD19 target played a part.
Thermo Fisher has bolstered its stem cell technology and reagent business through the acquisition of MTI-GlobalStem.
Content Provided by World Courier
Clinical trials have evolved and traditional models are becoming extinct. Read about the change and World Courier and MRN's patient-centric approach.